APO Research
Talk to an analyst

APO RESEARCH · REPORT

Consumer Healthcare Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Consumer Healthcare Drug Market Outlook and Growth Opportunities 2026

21 December 2025201 pages

Choose your research edition.

Industry ResearchConsumer Healthcare Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Consumer Healthcare Drug Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Consumer Healthcare Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Consumer Healthcare Drug Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Consumer Healthcare Drug Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Consumer Healthcare Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Consumer Healthcare Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Consumer Healthcare Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Consumer Healthcare Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Consumer Healthcare Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Consumer Healthcare Drug market include Takeda, Teva, Shanghai Pharmaceuticals, Sanofi, Johnson & Johnson, Merck & Co., Pfizer, Hualan Bio and North China Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Consumer Healthcare Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Consumer Healthcare Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Consumer Healthcare Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Consumer Healthcare Drug market.

Consumer Healthcare Drug Segment by Company

Takeda

Teva

Shanghai Pharmaceuticals

Sanofi

Johnson & Johnson

Merck & Co.

Pfizer

Hualan Bio

North China Pharmaceutical

Hengrui Medicine

GlaxoSmithKline

Bayer

AbbVie

Sinopharm Group

Livzon Group

Fosun Pharma

East China Medicine

CR Pharmaceutical

Consumer Healthcare Drug Segment by Type

Patch

Oral Liquid

Solid Preparations

Other

Consumer Healthcare Drug Segment by Application

Hospital

Retail Pharmacy

Other

Consumer Healthcare Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Consumer Healthcare Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Consumer Healthcare Drug key companies, revenue, market share, and recent developments.

3. To split the Consumer Healthcare Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Consumer Healthcare Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Consumer Healthcare Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Consumer Healthcare Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Consumer Healthcare Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Consumer Healthcare Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Consumer Healthcare Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Consumer Healthcare Drug industry.

Chapter 3: Detailed analysis of Consumer Healthcare Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Consumer Healthcare Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Consumer Healthcare Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Consumer Healthcare Drug Industry Trends Table 2. Consumer Healthcare Drug Industry Drivers Table 3. Consumer Healthcare Drug Industry Opportunities and Challenges Table 4. Consumer Healthcare Drug Industry Restraints Table 5. Global Consumer Healthcare Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Consumer Healthcare Drug Revenue Share by Company (2021-2026) Table 7. Global Consumer Healthcare Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Consumer Healthcare Drug Key Company Manufacturing Base & Headquarters Table 9. Global Consumer Healthcare Drug Company, Product Type & Application Table 10. Global Consumer Healthcare Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Consumer Healthcare Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Patch Table 15. Significant Companies of Oral Liquid Table 16. Significant Companies of Solid Preparations Table 17. Significant Companies of Other Table 18. Global Consumer Healthcare Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Consumer Healthcare Drug Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Consumer Healthcare Drug Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Consumer Healthcare Drug Sales Value Share by Type (2021-2026) Table 22. Global Consumer Healthcare Drug Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Retail Pharmacy Table 25. Significant Companies of Other Table 26. Global Consumer Healthcare Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Consumer Healthcare Drug Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Consumer Healthcare Drug Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Consumer Healthcare Drug Sales Value Share by Application (2021-2026) Table 30. Global Consumer Healthcare Drug Sales Value Share by Application (2027-2032) Table 31. Global Consumer Healthcare Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Consumer Healthcare Drug Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Consumer Healthcare Drug Sales Value Share by Region (2021-2026) Table 34. Global Consumer Healthcare Drug Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Consumer Healthcare Drug Sales Value Share by Region (2027-2032) Table 36. Global Consumer Healthcare Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Consumer Healthcare Drug Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Consumer Healthcare Drug Sales Value Market Share by Country (2021-2026) Table 39. Global Consumer Healthcare Drug Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Consumer Healthcare Drug Sales Value Market Share by Country (2027-2032) Table 41. Takeda Company Information Table 42. Takeda Business Overview Table 43. Takeda Consumer Healthcare Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Takeda Consumer Healthcare Drug Product Portfolio Table 45. Takeda Recent Development Table 46. Teva Company Information Table 47. Teva Business Overview Table 48. Teva Consumer Healthcare Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Teva Consumer Healthcare Drug Product Portfolio Table 50. Teva Recent Development Table 51. Shanghai Pharmaceuticals Company Information Table 52. Shanghai Pharmaceuticals Business Overview Table 53. Shanghai Pharmaceuticals Consumer Healthcare Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Shanghai Pharmaceuticals Consumer Healthcare Drug Product Portfolio Table 55. Shanghai Pharmaceuticals Recent Development Table 56. Sanofi Company Information Table 57. Sanofi Business Overview Table 58. Sanofi Consumer Healthcare Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Sanofi Consumer Healthcare Drug Product Portfolio Table 60. Sanofi Recent Development Table 61. Johnson & Johnson Company Information Table 62. Johnson & Johnson Business Overview Table 63. Johnson & Johnson Consumer Healthcare Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Johnson & Johnson Consumer Healthcare Drug Product Portfolio Table 65. Johnson & Johnson Recent Development Table 66. Merck & Co. Company Information Table 67. Merck & Co. Business Overview Table 68. Merck & Co. Consumer Healthcare Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Merck & Co. Consumer Healthcare Drug Product Portfolio Table 70. Merck & Co. Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Consumer Healthcare Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Pfizer Consumer Healthcare Drug Product Portfolio Table 75. Pfizer Recent Development Table 76. Hualan Bio Company Information Table 77. Hualan Bio Business Overview Table 78. Hualan Bio Consumer Healthcare Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Hualan Bio Consumer Healthcare Drug Product Portfolio Table 80. Hualan Bio Recent Development Table 81. North China Pharmaceutical Company Information Table 82. North China Pharmaceutical Business Overview Table 83. North China Pharmaceutical Consumer Healthcare Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. North China Pharmaceutical Consumer Healthcare Drug Product Portfolio Table 85. North China Pharmaceutical Recent Development Table 86. Hengrui Medicine Company Information Table 87. Hengrui Medicine Business Overview Table 88. Hengrui Medicine Consumer Healthcare Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Hengrui Medicine Consumer Healthcare Drug Product Portfolio Table 90. Hengrui Medicine Recent Development Table 91. GlaxoSmithKline Company Information Table 92. GlaxoSmithKline Business Overview Table 93. GlaxoSmithKline Consumer Healthcare Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. GlaxoSmithKline Consumer Healthcare Drug Product Portfolio Table 95. GlaxoSmithKline Recent Development Table 96. Bayer Company Information Table 97. Bayer Business Overview Table 98. Bayer Consumer Healthcare Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Bayer Consumer Healthcare Drug Product Portfolio Table 100. Bayer Recent Development Table 101. AbbVie Company Information Table 102. AbbVie Business Overview Table 103. AbbVie Consumer Healthcare Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. AbbVie Consumer Healthcare Drug Product Portfolio Table 105. AbbVie Recent Development Table 106. Sinopharm Group Company Information Table 107. Sinopharm Group Business Overview Table 108. Sinopharm Group Consumer Healthcare Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Sinopharm Group Consumer Healthcare Drug Product Portfolio Table 110. Sinopharm Group Recent Development Table 111. Livzon Group Company Information Table 112. Livzon Group Business Overview Table 113. Livzon Group Consumer Healthcare Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Livzon Group Consumer Healthcare Drug Product Portfolio Table 115. Livzon Group Recent Development Table 116. Fosun Pharma Company Information Table 117. Fosun Pharma Business Overview Table 118. Fosun Pharma Consumer Healthcare Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Fosun Pharma Consumer Healthcare Drug Product Portfolio Table 120. Fosun Pharma Recent Development Table 121. East China Medicine Company Information Table 122. East China Medicine Business Overview Table 123. East China Medicine Consumer Healthcare Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. East China Medicine Consumer Healthcare Drug Product Portfolio Table 125. East China Medicine Recent Development Table 126. CR Pharmaceutical Company Information Table 127. CR Pharmaceutical Business Overview Table 128. CR Pharmaceutical Consumer Healthcare Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. CR Pharmaceutical Consumer Healthcare Drug Product Portfolio Table 130. CR Pharmaceutical Recent Development Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Consumer Healthcare Drug Product Image Figure 2. Global Consumer Healthcare Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Consumer Healthcare Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Consumer Healthcare Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Patch Image Figure 8. Oral Liquid Image Figure 9. Solid Preparations Image Figure 10. Other Image Figure 11. Global Consumer Healthcare Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Consumer Healthcare Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Consumer Healthcare Drug Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Retail Pharmacy Image Figure 16. Other Image Figure 17. Global Consumer Healthcare Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Consumer Healthcare Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Consumer Healthcare Drug Sales Value Share by Application (2021-2032) Figure 20. Global Consumer Healthcare Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Consumer Healthcare Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Consumer Healthcare Drug Sales Value (2021-2032) & (US$ Million) Figure 23. North America Consumer Healthcare Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Consumer Healthcare Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Consumer Healthcare Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Consumer Healthcare Drug Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Consumer Healthcare Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Consumer Healthcare Drug Sales Value (2021-2032) & (US$ Million) Figure 29. South America Consumer Healthcare Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Consumer Healthcare Drug Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Consumer Healthcare Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Consumer Healthcare Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Patch
  • Oral Liquid
  • Solid Preparations
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Takeda
  • Teva
  • Shanghai Pharmaceuticals
  • Sanofi
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer
  • Hualan Bio
  • North China Pharmaceutical
  • Hengrui Medicine
  • GlaxoSmithKline
  • Bayer
  • AbbVie
  • Sinopharm Group
  • Livzon Group
  • Fosun Pharma
  • East China Medicine
  • CR Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Consumer Healthcare Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Consumer Healthcare Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Consumer Healthcare Drug Market Dynamics
  1. 2.1 Consumer Healthcare Drug Industry Trends
  2. 2.2 Consumer Healthcare Drug Industry Drivers
  3. 2.3 Consumer Healthcare Drug Industry Opportunities and Challenges
  4. 2.4 Consumer Healthcare Drug Industry Restraints
3 Consumer Healthcare Drug Market by Company
  1. 3.1 Global Consumer Healthcare Drug Company Revenue Ranking in 2025
  2. 3.2 Global Consumer Healthcare Drug Revenue by Company (2021-2026)
  3. 3.3 Global Consumer Healthcare Drug Company Ranking (2024-2026)
  4. 3.4 Global Consumer Healthcare Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Consumer Healthcare Drug Company Product Type and Application
  6. 3.6 Global Consumer Healthcare Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Consumer Healthcare Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Consumer Healthcare Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Consumer Healthcare Drug Market by Type
  1. 4.1 Consumer Healthcare Drug Type Introduction
  2. 4.1.1 Patch
  3. 4.1.2 Oral Liquid
  4. 4.1.3 Solid Preparations
  5. 4.1.4 Other
  6. 4.2 Global Consumer Healthcare Drug Sales Value by Type
  7. 4.2.1 Global Consumer Healthcare Drug Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Consumer Healthcare Drug Sales Value by Type (2021-2032)
  9. 4.2.3 Global Consumer Healthcare Drug Sales Value Share by Type (2021-2032)
5 Consumer Healthcare Drug Market by Application
  1. 5.1 Consumer Healthcare Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Consumer Healthcare Drug Sales Value by Application
  6. 5.2.1 Global Consumer Healthcare Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Consumer Healthcare Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Consumer Healthcare Drug Sales Value Share by Application (2021-2032)
6 Consumer Healthcare Drug Regional Value Analysis
  1. 6.1 Global Consumer Healthcare Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Consumer Healthcare Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Consumer Healthcare Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Consumer Healthcare Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Consumer Healthcare Drug Sales Value (2021-2032)
  7. 6.3.2 North America Consumer Healthcare Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Consumer Healthcare Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Consumer Healthcare Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Consumer Healthcare Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Consumer Healthcare Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Consumer Healthcare Drug Sales Value (2021-2032)
  16. 6.6.2 South America Consumer Healthcare Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Consumer Healthcare Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Consumer Healthcare Drug Sales Value Share by Country, 2025 VS 2032
7 Consumer Healthcare Drug Country-level Value Analysis
  1. 7.1 Global Consumer Healthcare Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Consumer Healthcare Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Consumer Healthcare Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Consumer Healthcare Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Consumer Healthcare Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Consumer Healthcare Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Consumer Healthcare Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Consumer Healthcare Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Consumer Healthcare Drug Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Shanghai Pharmaceuticals
  14. 8.3.1 Shanghai Pharmaceuticals Company Information
  15. 8.3.2 Shanghai Pharmaceuticals Business Overview
  16. 8.3.3 Shanghai Pharmaceuticals Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Pharmaceuticals Consumer Healthcare Drug Product Portfolio
  18. 8.3.5 Shanghai Pharmaceuticals Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Consumer Healthcare Drug Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Consumer Healthcare Drug Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Merck & Co.
  32. 8.6.1 Merck & Co. Company Information
  33. 8.6.2 Merck & Co. Business Overview
  34. 8.6.3 Merck & Co. Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co. Consumer Healthcare Drug Product Portfolio
  36. 8.6.5 Merck & Co. Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Consumer Healthcare Drug Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Hualan Bio
  44. 8.8.1 Hualan Bio Company Information
  45. 8.8.2 Hualan Bio Business Overview
  46. 8.8.3 Hualan Bio Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hualan Bio Consumer Healthcare Drug Product Portfolio
  48. 8.8.5 Hualan Bio Recent Developments
  49. 8.9 North China Pharmaceutical
  50. 8.9.1 North China Pharmaceutical Company Information
  51. 8.9.2 North China Pharmaceutical Business Overview
  52. 8.9.3 North China Pharmaceutical Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 North China Pharmaceutical Consumer Healthcare Drug Product Portfolio
  54. 8.9.5 North China Pharmaceutical Recent Developments
  55. 8.10 Hengrui Medicine
  56. 8.10.1 Hengrui Medicine Company Information
  57. 8.10.2 Hengrui Medicine Business Overview
  58. 8.10.3 Hengrui Medicine Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hengrui Medicine Consumer Healthcare Drug Product Portfolio
  60. 8.10.5 Hengrui Medicine Recent Developments
  61. 8.11 GlaxoSmithKline
  62. 8.11.1 GlaxoSmithKline Company Information
  63. 8.11.2 GlaxoSmithKline Business Overview
  64. 8.11.3 GlaxoSmithKline Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GlaxoSmithKline Consumer Healthcare Drug Product Portfolio
  66. 8.11.5 GlaxoSmithKline Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Consumer Healthcare Drug Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 AbbVie
  74. 8.13.1 AbbVie Company Information
  75. 8.13.2 AbbVie Business Overview
  76. 8.13.3 AbbVie Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AbbVie Consumer Healthcare Drug Product Portfolio
  78. 8.13.5 AbbVie Recent Developments
  79. 8.14 Sinopharm Group
  80. 8.14.1 Sinopharm Group Company Information
  81. 8.14.2 Sinopharm Group Business Overview
  82. 8.14.3 Sinopharm Group Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Sinopharm Group Consumer Healthcare Drug Product Portfolio
  84. 8.14.5 Sinopharm Group Recent Developments
  85. 8.15 Livzon Group
  86. 8.15.1 Livzon Group Company Information
  87. 8.15.2 Livzon Group Business Overview
  88. 8.15.3 Livzon Group Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Livzon Group Consumer Healthcare Drug Product Portfolio
  90. 8.15.5 Livzon Group Recent Developments
  91. 8.16 Fosun Pharma
  92. 8.16.1 Fosun Pharma Company Information
  93. 8.16.2 Fosun Pharma Business Overview
  94. 8.16.3 Fosun Pharma Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Fosun Pharma Consumer Healthcare Drug Product Portfolio
  96. 8.16.5 Fosun Pharma Recent Developments
  97. 8.17 East China Medicine
  98. 8.17.1 East China Medicine Company Information
  99. 8.17.2 East China Medicine Business Overview
  100. 8.17.3 East China Medicine Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 East China Medicine Consumer Healthcare Drug Product Portfolio
  102. 8.17.5 East China Medicine Recent Developments
  103. 8.18 CR Pharmaceutical
  104. 8.18.1 CR Pharmaceutical Company Information
  105. 8.18.2 CR Pharmaceutical Business Overview
  106. 8.18.3 CR Pharmaceutical Consumer Healthcare Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 CR Pharmaceutical Consumer Healthcare Drug Product Portfolio
  108. 8.18.5 CR Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst